MedPath

To study the effect of postoperative pain following breast surgery using local anaesthestic infiltratio

Phase 3
Conditions
Health Condition 1: null- breast cancer
Registration Number
CTRI/2017/08/009401
Lead Sponsor
Monisha B J Neelankavil
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

breast cancer patients undergoing modified radical mastectomy

Exclusion Criteria

Known hypersensitivity or contraindication to Bupivacaine or Dexmedetomidine; pregnancy, drug allergy, cardiac patients, renal patients, significant pulmonary diseases, bleeding diathesis, psychological, neurological, metabolic diseases,Chronic analgesic drug abuse (on oral analgesics for more than a month).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1)To compare the postoperative analgesic effects of bupivacaine following mastectomy <br/ ><br>2)To compare the postoperative analgesic effects of dexmedetomidine following mastectomy <br/ ><br>3)To compare the postoperative analgesic effect of Bupivacaine combined with Dexmedetomidine following mastectomy. <br/ ><br>4)To compare the requirement of analgesics following mastectomy between the two groups for 24 hours <br/ ><br>Timepoint: visual analogue score of more than 5
Secondary Outcome Measures
NameTimeMethod
1)To compare the postoperative analgesic effects of bupivacaine following mastectomy <br/ ><br>2)To compare the postoperative analgesic effects of dexmedetomidine following mastectomy <br/ ><br>3)To compare the postoperative analgesic effect of Bupivacaine combined with Dexmedetomidine following mastectomy. <br/ ><br>4)To compare the requirement of analgesics following mastectomy between the two groups for 24 hours <br/ ><br>Timepoint: ramsay sedation scale of 2 or 3 <br/ ><br>modified aldrete score more than 9
© Copyright 2025. All Rights Reserved by MedPath